1. Home
  2. RLGT vs IMMP Comparison

RLGT vs IMMP Comparison

Compare RLGT & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Radiant Logistics Inc.

RLGT

Radiant Logistics Inc.

HOLD

Current Price

$6.69

Market Cap

291.6M

ML Signal

HOLD

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$2.57

Market Cap

264.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RLGT
IMMP
Founded
2001
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Oil Refining/Marketing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
291.6M
264.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RLGT
IMMP
Price
$6.69
$2.57
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$8.00
N/A
AVG Volume (30 Days)
154.2K
1.7M
Earning Date
11-10-2025
02-22-2026
Dividend Yield
N/A
N/A
EPS Growth
72.35
N/A
EPS
0.31
N/A
Revenue
$925,786,000.00
$3,306,742.00
Revenue This Year
$3.77
N/A
Revenue Next Year
$3.51
N/A
P/E Ratio
$21.55
N/A
Revenue Growth
16.42
31.28
52 Week Low
$5.44
$1.32
52 Week High
$7.94
$3.53

Technical Indicators

Market Signals
Indicator
RLGT
IMMP
Relative Strength Index (RSI) 68.13 72.34
Support Level $6.31 $1.67
Resistance Level $6.49 $2.68
Average True Range (ATR) 0.16 0.25
MACD 0.06 0.09
Stochastic Oscillator 83.16 48.12

Price Performance

Historical Comparison
RLGT
IMMP

About RLGT Radiant Logistics Inc.

Radiant Logistics Inc operates as a third-party logistics company, providing multi-modal transportation and logistics services to customers based in the United States and Canada. The company offers domestic and international air and ocean freight forwarding services and freight brokerage services including truckload services, less-than-truckload (LTL) services, and intermodal services. It has two geographic operating segments: the United States and Canada. Maximum revenue is generated in the United States.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: